[
    {
        "file_name": "ANIXABIOSCIENCESINC_06_09_2020-EX-10.1-COLLABORATIONAGREEMENT.txt",
        "perturbation": [
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "3.1 Research Program Payments. In consideration for OntoChem's performance of its activities under the Research Plan, Anixa will:\n\n(a) pay OntoChem 100,002 Euros in six (6) equal installments as follows: (i) 16,667 Euros within five (5) days after the Effective Date; and (ii) five (5) installments in the amount of 16,667 Euros on each one-month anniversary of the Effective Date, except that the last such payment will be due within thirty (30) days after completion of all activities under the Research Plan;",
                "changed_text": "3.1 Research Program Payments. In consideration for OntoChem's performance of its activities under the Research Plan, Anixa will:\n\n(a) pay OntoChem 100,002 Euros in six (6) equal installments as follows: (i) 16,667 Euros within five (5) days after the Effective Date; and (ii) five (5) installments in the amount of 16,667 Euros on each one-month anniversary of the Effective Date, except that the last such payment will be due within fifteen (15) days after completion of all activities under the Research Plan;",
                "explanation": "This creates a contradiction regarding the deadline for the final payment. Initially, the final payment is due within 'thirty (30) days' after completion of all activities, but now it states 'fifteen (15) days' creating an ambiguity that may lead to a dispute regarding payment timelines.",
                "location": "Section 3.1"
            },
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "3.2 Lead Scaffold Payments. For each Lead Scaffold selected by Anixa, Anixa will pay OntoChem an annual fee of 10,000 U.S. Dollars, payable within thirty (30) days following each anniversary of the date of the Selection Notice, until five (5) years after the first commercial sale of the first product incorporating a compound from such Lead Scaffold, subject to Section 4.3 with respect to any Terminated Scaffold (as defined below).\n\n3.3 Milestone Payment. Anixa will pay OntoChem a one-time milestone payment of 300,000 U.S. Dollars within thirty (30) days following the dosing of the first patient in the first human clinical trial for the first product incorporating a compound from a Lead Scaffold.",
                "changed_text": "3.2 Lead Scaffold Payments. For each Lead Scaffold selected by Anixa, Anixa will pay OntoChem an annual fee of 10,000 U.S. Dollars, payable within sixty (60) days following each anniversary of the date of the Selection Notice, until five (5) years after the first commercial sale of the first product incorporating a compound from such Lead Scaffold, subject to Section 4.3 with respect to any Terminated Scaffold (as defined below).\n\n3.3 Milestone Payment. Anixa will pay OntoChem a one-time milestone payment of 300,000 U.S. Dollars within thirty (30) days following the dosing of the first patient in the first human clinical trial for the first product incorporating a compound from a Lead Scaffold.",
                "explanation": "Changing 'thirty (30) days' to 'sixty (60) days' for the Lead Scaffold Payment contradicts the 'thirty (30) days' for the Milestone Payment. This creates a contradiction about when payments are due and adds confusion in enforcement.",
                "location": "Section 3.2"
            },
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "4.2 Termination by Anixa. This Agreement may be terminated by Anixa, without cause, upon at least thirty (30) days written notice to OntoChem.\n\n4.3 Termination of Lead Scaffolds. For each Lead Scaffold, if (a) neither Anixa nor any of its Affiliates, licensees or assignees has dosed the first patient in a human clinical trial for a product incorporating a compound from such Lead Scaffold by the fifth (5th) anniversary of the date of the Selection Notice, or (b) Anixa earlier provides written notice of termination of such Lead Scaffold referencing this Section 4.3, then such Lead Scaffold (each, a \"Terminated Scaffold\") will thereupon cease to be a Lead Scaffold under this Agreement and thereafter, notwithstanding anything to the contrary in this Agreement: (i) Anixa will promptly assign to OntoChem all right, title and interest in and to any patents and patent applications owned by Anixa that claim such Terminated Scaffold (including the composition, use or manufacture thereof) and, following such assignment, OntoChem will exclusively control the filing, prosecution, maintenance and enforcement of such patents and patent applications; (ii) the identity, structure and SAR information of such Terminated Scaffold will be deemed to be the Confidential Information of OntoChem; (iii) Anixa will not owe any further annual fees under Section 3.2 for such Terminated Scaffold; and (iv) this Agreement will otherwise remain in full force and effect.",
                "changed_text": "4.2 Termination by Anixa. This Agreement may be terminated by Anixa, without cause, upon at least thirty (30) days written notice to OntoChem.\n\n4.3 Termination of Lead Scaffolds. For each Lead Scaffold, if (a) neither Anixa nor any of its Affiliates, licensees or assignees has dosed the first patient in a human clinical trial for a product incorporating a compound from such Lead Scaffold by the fifth (5th) anniversary of the date of the Selection Notice, or (b) Anixa earlier provides written notice of termination of such Lead Scaffold referencing this Section 4.3, then such Lead Scaffold (each, a \"Terminated Scaffold\") will thereupon cease to be a Lead Scaffold under this Agreement and thereafter, notwithstanding anything to the contrary in this Agreement: (i) Anixa will promptly assign to OntoChem all right, title and interest in and to any patents and patent applications owned by Anixa that claim such Terminated Scaffold (including the composition, use or manufacture thereof) and, following such assignment, OntoChem will exclusively control the filing, prosecution, maintenance and enforcement of such patents and patent applications; (ii) the identity, structure and SAR information of such Terminated Scaffold will be deemed to be the Confidential Information of Anixa; (iii) Anixa will not owe any further annual fees under Section 3.2 for such Terminated Scaffold; and (iv) this Agreement will otherwise remain in full force and effect.",
                "explanation": "By modifying clause (ii) in Section 4.3 to state that the identity, structure, and SAR information of a Terminated Scaffold will be deemed the Confidential Information of 'Anixa' (instead of OntoChem) an inconsistency has been introduced. This contradicts the implied understanding in other sections (e.g., Section 6.2) that OntoChem retains certain rights and ownership over aspects of rejected or terminated scaffolds. It is now uncertain to whom this information belongs.",
                "location": "Section 4.3"
            }
        ]
    }
]